ImmuCell Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing was signed March 30, 2022. Although the request identifies 2021 Q4, this is an annual report; selected fourth-quarter results are noted below.
Business context
ImmuCell develops and sells animal-health products for dairy and beef cattle. Its established First Defense product line prevents scours in newborn calves; Re-Tain, a treatment for subclinical mastitis in lactating dairy cows, remained under FDA review and had no sales in 2021. First Defense represented 98% of FY2021 product sales.
Financial performance and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Product sales | $19.243 million | $15.342 million | +25% |
| Gross margin | $8.656 million; 45% | $6.863 million; 45% | +26% in dollars |
| Operating income (loss) | $257,000 | ($1.380 million) | Improved $1.638 million |
| Net loss | ($78,000); ($0.01) per share | ($1.022 million); ($0.14) per share | Loss narrowed |
| Operating cash flow | $954,000 | $1.316 million | Down $361,000 |
| Capital expenditures | $2.609 million | $4.073 million | Down $1.464 million |
Fourth-quarter product sales were $5.444 million, up 45% year over year; gross margin was $2.561 million, or 47%, versus $1.621 million, or 43%. The filing text does not provide a clear fourth-quarter net income value.
At year-end, cash and cash equivalents were $10.185 million (versus $7.946 million in cash and short-term investments in 2020), working capital was $13.730 million, total assets were $44.466 million, and stockholders’ equity was $32.577 million. Debt obligations were $9.139 million, including $812,000 current and $8.327 million long-term; operating lease liabilities were $1.135 million. The company reported positive operating cash flow, but investing activities used $1.597 million and financing provided $3.879 million, including $4.233 million net proceeds from an equity offering and $400,000 of state loan proceeds.
Interest expense was $314,000, down from $413,000. The 2020 comparison included $938,000 of forgiven PPP debt, so the change in net loss reflects both operating improvement and a prior-year unusual benefit. The company reported a full valuation allowance against deferred tax assets and federal net operating loss carryforwards of approximately $14.7 million.
Material changes and operating developments
- Sales grew domestically 22% and internationally 55%; international sales rose to 14% of total sales from 11%.
- First Defense sales were constrained by production capacity and supply-chain issues. The estimated order backlog was $2.4 million at year-end and $2.8 million on March 18, 2022; management cautioned that distributor ordering patterns make backlog less comparable.
- First Defense annual production capacity reached an estimated $23 million by year-end. Projects were intended to raise capacity to about $30 million by September 2022 and $35 million by December 2022, subject to execution, yields and product mix.
- Gross margin was 39% in Q1 2021, then improved to 46% in Q2 and 47% in each of Q3 and Q4. Management cited higher input, labor and supply costs, biological yield variability, and the greater cost of gel formats.
Outlook, risks and contingencies
- Re-Tain approval and launch: Four of five principal FDA technical sections were complete. The company resubmitted the outstanding Chemistry, Manufacturing and Controls section in Q1 2022 after an FDA incomplete letter in Q3 2021. Management expected an FDA response around August 2022; approval and launch timing remained uncertain. Its Re-Tain sales scenario—approximately $1 million in 2023 and about twice that in 2024—assumes approval and launch around the beginning of Q4 2022.
- Manufacturing transition: Norbrook’s supply agreement ends in 2022. ImmuCell is investing approximately $4 million in internal formulation and aseptic-filling capability; FDA approval was expected in Q4 2023 or Q2 2024. Delays or approval issues could affect supply and launch plans.
- Management targets: The company aims for annual gross margin above 46% as expanded production is utilized, with a longer-term goal approaching 50% before related depreciation and amortization. It also cited objectives of approximately $23 million in current annual product sales and more than $35 million within five years after a Re-Tain launch; these are goals, not assured forecasts.
- Debt and covenant risk: Bank debt was primarily fixed-rate at 3.50%. The company warned it might not meet its former 1.35 debt-service-coverage covenant in 2022; following a March 2022 financing, the required ratio was reduced to 1.0 for that year. The March 2022 mortgage amendment added $2 million and set a 3.53% blended rate, with a balloon payment due in 2032. Management stated liquidity should fund planned operations and capital needs for at least 12 months from filing.
- Concentration and demand: Two distributors accounted for 74% of FY2021 sales (46% and 28%); together they represented 72% of year-end receivables. First Defense depends on one product category and cattle-market economics. Backlogs risk customer loss, while later inventory build-up could create different working-capital and demand risks.
- Other risks: Supply-chain disruption, inflation, labor availability, customer affordability, biological production variability, competition from larger companies, regulatory compliance, product acceptance, and potential milk-tank or cheese-production issues associated with Re-Tain. The filing reports no material pending legal proceedings. The auditor issued an unqualified opinion and identified inventory valuation as a critical audit matter because of yield-related cost variability. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- FDA’s response to the resubmitted Re-Tain manufacturing section, final approval timing, and whether launch assumptions remain achievable.
- Actual progress in reducing the First Defense backlog, achieving planned production capacity, and retaining customers during shortages.
- Whether gross margins recover as planned despite input-cost inflation and variable biological yields.
- Availability and timing of Norbrook supply through 2022 and FDA approval of ImmuCell’s internal drug-product facility.
- Cash use, debt service, 2022 covenant compliance, and the effect of the March 2022 mortgage financing on liquidity.
- Distributor concentration, receivable collection, and the sustainability of sales growth and the Re-Tain projections.